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Original Articles 
A COMPARATIVE TRIAL OF SINGLE DOSE CHEMOTHERAPY 
IN PAUCIBACILLARY LEPROSY PATIENTS WITH TWO TO 
THREE SKIN LESIONS 
2-3 Lesion Multicentre Trial Group* 
to compare the efficacy of a combination of rifampicin 600 mg plus ofloxacin 
400 mg plus minocycline 100 mg (ROM) administered as single dose with 
that of standard WHO/MDT/PB six months regimen. The study subjects were 
236 previously untreated, smear-negative patients, without nerve trunk 
involvement and having only two or three skin lesions. Randomization was 
done on individual patient basis. Results were analyzed for mean clincal 
score for improvement, marked clinical improvement and complete clinical 
cure at the time of release from treatment and at 12 months and 18 months 
of follow-up. 
Clinical improvement was seen in most patients in both regimens. Marked 
improvement (i.e., more than 90% reduction in clinical score) at 18 months 
was seen in 46.2% and 53.4% of the patients treated with ROM and standard 
regimens, respectively. But, significant difference in favour of standard PB 
regimen was seen in patients with three skin lesions and in patients in whom 
more than one body part was affected. Reversal reaction and adverse drug 
reactions were minimal in both groups. 
An international study group convened in October 1981 by World Health 
Organization (WHO) made a significant recommendation that patients with 
paucibacillary (PB) leprosy should be treated for six months with a combination 
of two drugs, dapsone (daily) and rifampicin (monthly). With the introduction 
of multidrug therapy (MDT) since then, prevalence of leprosy has dramatically 
declined. With this regimen, the relapse rate among patients with PB leprosy 
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is only around 1% over nine years of suryeillance (WHO 1995). Attention 
was still focussed on two issues, drug compliance among patients with PB 
leprosy and further shortening the duration of chemotherapy for PB leprosy, 
especially for cases with a single lesion. The search for newer drugs and 
shorter regimens therefore, continued. During the last decade, a large number 
of bactericidal drugs have been tested for anti M. leprae activity and their 
potential for clinical use (Gelber 1987, Grosset et al 1988, Franzblau & White 
1990). It has been shown that monthly dose of rifampicin, 600 mg, is almost 
as effective as daily rifampicin (Ji et al 1996). It has been established that 
a single dose of rifampicin (600 mg) exerts a very strong bactericidal effect 
on M. leprae (Levy et a1 1976, Ji et al 1992). Addition of ofloxacin 400 mg 
and minocycline 100 mg, has the potential to prevent the selection of rifampicin- 
resistant mutants, if any, in skin-smear negative PB leprosy where the bacterial 
population is expected to be well below one million (WHO 1982). It has been 
shown in a multicentric double-blind controlled clinical trial that a combination 
of rifampicin, ofloxacin and minocycline (ROM), administered as a single 
dose, was almost as effective as the standard six-month PB/MDT regimen 
in the treatment of single-lesion PB leprosy, and the frequency of occurrence 
of mild side-effects and leprosy reactions was less than 1% with the single 
dose ROM regimen (Single Lesion Multicentre Trial Group 1997). Since PB 
leprosy constitutes the major part of the case load in endemic regions, it was 
considered to extend this regimen to cover patients with two to three skin 
lesions in whom also the number of leprosy bacilli is expected to be well 
below one million and a single dose ROM might be sufficient to treat these 
patients. 
A multicentric double-blind randomized controlled clinical trial was 
undertaken with the objective to compare the efficacy of ROM, administered 
as a single dose, with that of the standard six-months WHO PB/MDT regimen 
in the treatment of PB leprosy patients with 2-3 skin lesions. 
MATERIAL AND METHOD 
PATIENTS 
Based on clinical and bacteriological examination, PB leprosy patients 
with two or three skin lesions, who were skin-smear negative, and were 
previously untreated and having no evidence of any peripheral nerve trunk 
involvement (no nerve trunk thickened/tender), were included in the trial. 
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Children below five years of age, pregnant women, patients known to be 
allergic to any of the proposed drugs or their derivatives, and those who were 
HIV positive (if tested), were excluded from the trial. 
SAMPLES 
In all, 236 patients were included in the study, 118 each to the study 
group (ROM single dose) and the control group (WHO/PB regimen) by 
random allocation. It was necessary to have a sample size of atleast 100 
patients in each arm for equivalence study for 50% efficacy in terms of 
complete clearance of lesions with 80% of power and 20% permissible 
difference (µ =0.05). 
REGIMEN 
ROM (Study) Regimen: rifampicin (600 mg), ofloxacin (400 mg) and 
minocycline (100 mg), administered as a single dose (Children were given 
half the dose). 
Standard (Control) Regimen: six-months WHO PB/MDT, i.e. rifampicin 
(600 mg) monthly and dapsone (100 mg) daily for six months (children were 
given appropriate dose). 
PARTICIPATING CENTRES 
Five centres participated in the study, namely, CJIL Field Unit (now part 
of NIE, ICMR), Avadi, District Leprosy Officer, Chennai city, The Leprosy 
Mission Hospitals at Barabanki and Naini and Tuberculosis Research Centre 
(ICMR), Chennai. 
TRIAL PROCEDURE 
Intake of patients was spread over seven months, from October 1995 to 
April 1996. Information on patient identification particulars and medical 
history was collected and informed consent obtained. In all, 236 patients (1 63 
adults and 73 children), from the five centres were allocated randomly to 
either of the two regimens following random permutation of two digits (0,1) 
by using Statistical Tables for Biological and Medical Research by Fisher & 
Yates. All patients, in both the regimens, were "treated" for six months, with 
appropriate drugs and identical looking placebo preparations. The 
administration of drugs (including placebo) at the monthly visits was fully 
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supervised in blinded fashion, in both regimens. Patients completing six 
months treatment within nine months were considered “regular”. 
CLINICAL SCORING 
Each patient was assessed at four points of time, at admission, at six 
months (release from treatment or RFT), at 12 months and at 18 months. For 
each lesion, the maximum possible score at intake was 18 and the minimum 
score at follow-up was 0. Each patient was clinically assessed and scores were 
given as shown in table I. 
Table I. Details of clinical scoring followed in the study 
Score awarded in Clinical feature 
Marked Moderate Mild Nil 
1. Hypopigmentation 3 2 1 0 
2. Erythema 3 2 1 0 
3. Infiltration 3 2 1 0 
4. Appearance of lesion 3 2 1 0 
(Clearly visible) (Faintly visible) (Doubtful) Nil 
5. Anaesthesia 3 2 1 0 
(Complete loss) (Definite impairment) (Doubtful impairment)(No loss) 
6. Size (Area of lesion » Length x Breadth): Initial score: 3. For every upto 20% increase or decrease, 
add or subtract 0.5; lesion disappeared: 0. 
The above scoring system is somewhat different from the one previously 
used in the single lesion study (Single Lesion Multicentre Trial Group 1997). 
In the single lesion trial, for the parameter hypopigmentation - erythema - 
infiltration, the highest possible score assigned at intake was 3. Thus at follow 
up deterioration in terms of clinical scores on each component could not be 
assessed. To overcome this problem separate grading was given at intake 
itself for each of the above parameters. 
OUTCOME MEASURES 
Following outcome measures were considered for assessing the efficacy 
of the regimens: (1) improvement in terms of reduced clinical score, (2) 
complete disappearance of all lesions and (3) treatment failure (i.e. smear 
positivity or appearance of new lesion/lesions at any point of time during 
follow-up, or no improvement or worsening in disease status at the end of 
study). 
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Patients confirmed as treatment failures were put on the appropriate 
standard WHO MDT regimen. 
IMPLEMENTATION AND DATA ANALYSIS 
The multicentre trial had an overall trial coordinator to ensure that the 
trial protocol was followed uniformly in all the centres. Reporting forms were 
collected, monitored and compiled at the then CJIL Field Unit, Avadi (now 
part of National Institute of Epidemiology (ICMR), Chennai). Fisher’s exact 
test or Chi-square test was employed for comparing proportions. Student’s 
t-test (if permissible) or Mann-Whitney U test was used to test significance 
of difference between two means. 
RESULTS 
DISTRIBUTION OF PATIENTS IN THE TWO GROUPS 
Of the 236 patients admitted into the study, 118 each were (randomly) 
allocated to the control standard regimen and study (ROM regimen) groups. 
The distribution of patients in the two groups by various factors at admission 
is shown in table II. It can be seen that the two groups of patients were similar 
with respect to age, sex, number of lesions and mean total clinical score at 
intake. 
Table II. Comparison of patients in the two groups at the time of admission 
Variable Control group Study group P value 
Adult 82 (69.5%) 81 (68.4%) 1.000 
Child 36 (30.5%) 37 (31.6%) 
Males 60 (50.8%) 49 (41.0%) 0.192 
Females 58 (49.3%) 69 (59.0%) 
Age 
Sex 
No. of lesions 
Two 82 (69.5%) 87 (73.7%) 0.564 
Three 36 (30.5%) 31 (26.3%) 
Mean of total score 26.74 26.65 0.895 
SD 7.75 7.05 
Clinical score 
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COVERAGE 
Two hundred seventeen of the 236 patients admitted (92%), 209 (89%) 
and 207 (88%) were followed up at six, 12 and 18 months respectively (table 
III). Losses were more at the two urban centres from Chennai. 
Table III. In-take and foIlowed-up according to participating centre 
Follow-up period Participating centre 
Intake 6 mo 12 mo 18 mo 
Barabanki 23 22 22 22 
Chennai 54 50 44 42 
CJIL 62 59 59 59 
Naini 51 48 46 47 
TRC 46 38 38 37 
All centres 236 217 209 207 
(100.0) (91.9) (88.6) (87.7) 
Numbers indicate the number of patients; figures in brackets give percentages. 
Out of the 29 the patients lost to follow-up (15 from the control and 14 
from the study groups), five refused treatment after initiation of therapy, 16 
left the area and three patients were absent during follow-up. Among the five 
refusals, four belong to the study group (ROM regimen) and one to the control 
group (WHO regimen). The exact reason for refusal could not be ascertained. 
However, to the best of our knowledge none of these patients had discontinued 
because of side effects. In three patients, treatment was discontinued because 
of cancer, jaundi d anaemia respectively. In two patients, treatment was 
discontinued because of side effects (rashes, “flu” syndrome). 
CLINICAL RESPONSE 
Table IV gives separately the mean total clinical scores at intake, six, 
12 and 18 months follow-up for the patients under the two regimens. In both 
the regimens, the mean clinical score decreased substantially over the 18 
months: from 26.74 to 4.76 and from 26.65 to 5.52 in the control and study 
group respectively. The difference between the mean values of the two groups 
at each of the four rounds was not statistically significant. 
It is also seen that the decrease in the mean values were similar, at each 
of the three follow-ups, in the two groups of patients under the two treatment 
regimens. The distribution of patients by the difference in total score at intake 
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Table VI. Mean total score at each assessmnt 
Control group Study group P value Assessment done 
(Standard regimen) (ROM regimen) 
At intake n 118 118 
.65 0.895 
At 6 months n 108 109 
Mean score 10.51 10.30 0.802 
(S.D.) (7.78) (7.91) 
At 12 months n 102 107 
Mean score 6.81 6.95 0.691 
(S.D.) (7.59) (7.16) 
At 18 months n 103 104 
Mean score 4.76 5.52 0.295 
(S.D.) (6.45) (6.60) 
and at 18 months separately for patients under the imens is shown 
in Fig. 1. The two curves are quite similar, more or 1 iding with each 
other, showing that the overall evolution of clinical score, over 18 months, 
among patients under the two regimen was similar. 
Fig. 1. Distribution of patients by difference in total score at intake and at 18 months. 
Marked improvement: A patient was considered to have “markedly” 
improved at 18 months if there was more than 90% reduction in the initial 
total clinical score. It can be seen that there was marked improvement in the 
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disease status at 18 months (table V) in 55 of the 103 patients (53.4%) in 
the control group getting standard regimen, compared with 48 of the 104 
patients (46.2%) in the study group getting the ROM regimen (single dose). 
This difference is not statistically significant (P=0.3). 
Table V. Distribution of ‘‘marked improvement” in the two groups 
Control group Study group 
Improvement status (Standard regimen) (ROM regimen) 
No. % No. % 
Marked improvement* 55 (53.4) 48 (46.2) 
No “marked improvement” 48 (46.6) 56 (53.8) 
Total 103 (100.0) 104 (100.0) 
* “Marked improvement” defined as more than 90% reduction in the initial score at 18 months. 
Complete cure: Complete cure was defined as “total disappearance of 
all lesions (i.e. total clinical score of zero) at 18 months”. For patients in the 
control group under standard PB regimen, the proportions with complete cure 
were 12% at six months, increasing to 31% at 12 months and 46% at 18 
months. For patients in the study group under ROM regimen, the corresponding 
figures were lo%, 25% and 38% at six, 12 and 18 months respectively (Fig. 
2). Table VI gives the percentage of patients completely cured in the two 
Fig. 2. Percentage of patients with complete clearance or the lesion. 
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groups according to age, number of lesions and number of body parts involved. 
Among child patients, 36.4% under standard regimen (control group) were 
completely cured compared with 40.0% under ROM regimen (study group) 
(P=0.95). However, among adult patients the corresponding figures were 
50.0% for the control group and 36.2% for the study group (P=0.14). 
Table VI. Percentage of patients in the two groups showing complete clearance of lesions at 18 
months for the two regimens 
Factor Control group Study group P value 
(Standard regimen) (ROM regimen) 
AGE 
Child 36.4 
Adult 50.0 
All 45.6 
Two 42.9 
Three 51.5 
One 44.2 
Two 59.1 
Three 
NO. OF LESIONS 
NO. OF BODY PARTS INVOLVED 
(12/33) 
(47/103) 
85/70) 
(30/70) 
(1 7/33) 
(34/77) 
(1 3/22) 
(0/4) 
40.0 (14/35) 
36.2 (25/69) 
37.5 (39/104) 
39.5 (30/76) 
32.1 (9/28) 
44.6 (33/74) 
21.4 (6/28) 
(0/2) 
0.953 
0.142 
0.296 
0.805 
0.206 
0.9 12 
0.015 
Total 45.6 (47/103) 37.5 (39/104) 0.296 
Figure in brackets gives actual number of patients / total in that set. 
Considering the number of lesions, in patients with two lesions, 42.9% 
of those getting the standard regimen (control group) were completely cured 
compared with 39.5% getting the ROM regimen (study group) (P=0.8). 
Among patients with three lesions, the corresponding figures were 5 1.5% for 
standard regimen (control group) and 32.1 % for ROM regimen (study group) 
(P=0.21) 
Considering the number of body parts involved, among patients in whom 
only one body part was involved, the proportions of patients completely cured 
were similar in the two groups, they being 44.2% and 44.6% in the control 
and study groups respectivey (P=0.91). Among patients in whom two body 
parts were involved, the corresponding figures were 59.1% and 21.4% for 
the control and study groups respectively. This difference was statistically 
significant (P=0.015). There were only six patients in whom three body parts 
were involved and it was interesting to note that in none of them complete 
cure was seen. 
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Treatment failure: There were eight cases of treatment failure (3.8%) 
among the 210 patients who had completed the 18 months follow-up (table 
VII). They were equally distributed in the two groups, four (3.8%) of the 104 
patients under the standard regimen and four (3.8%) of the 106 patients under 
the ROM regimen. Among those who had WHO/PB/MDT, three showed no 
clinical improvement and one patient had become smear-positive (BI 0.33). 
In the study group, two patients showed no clinical improvement and one 
had become smear-positive (BI 0.67); and new lesions had appeared in one 
patient (table VII). In both smear-positive patients (one each from the two 
groups) identified at the time of RFT, skin smear was positive only at one 
site and no clinical deterioration was seen during subsequent follow-up. All 
“treatment failure” cases were administered standard MDT. 
Table VII. Clinical details of treatment failures 
Control group Study group 
No. % No. % 
Clinical details (Standard regimen) (ROM regimen) 
No improvement in clinical score at 18 mo. 3 2 
Smear positive (BI at RFT) 1 1 
New lesions (at RFT) - 
Total no. of treatment failures 4 (3.8) 4 (3.8) 
No. of patients improved in clinical score 100 (96.2) 102 (96.2) 
Total 104 (100.0) 106 (100.0) 
1 
SIDE EFFECTS AND REVERSAL REACTIONS 
Side effects and reversal reactions were very few. None of the patients 
in the study group under ROM regimen suffered any adverse reactions. 
Among patients those in the control group (under standard regimen), one case 
of “flu” syndrome and one case of bullous eruptions were reported. Two adult 
patients treated with ROM regimen reported with type- 1 reaction. One patient 
was treated with a short course of steroid while the other did not require any 
anti-reaction treatment. 
DISCUSSION 
This study was undertaken to compare the efficacy of the single-dose 
ROM regimen with that of the standard six months WHO/PB/MDT regimen 
in the treatment of smear-negative PB leprosy patients having only two or 
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three skin lesions and no nerve trunk involvement. The assessment was made 
in terms of reduction in disease status based on clinical score according to 
set criteria, complete disappearance of all 1esions and treatment failure. 
Treatment failures were few and were equally distributed in the two groups. 
In assessing drug regimens in single lesion cases one would look for changes 
in clinical score in the lesion. In patients with two or three skin lesions one 
must look for clinical improvement considering. the patient as a whole. In 
routine smear examinations starting with a random smear field, there is a 
possibility of missing occasional bacilli. Therefore, standardized smear 
examination procedures by trained and standardized technicians were carried 
out and grading of the smear positivity was done according to Ridley scale. 
The results of the study showed that a single dose of rifampicin (600 mg), 
ofloxacin (400 mg) and minocycline (100 mg) was almost as effective as the 
standard six-months WHO-multidrug regimen for PB leprosy, in terms of 
mean reduction in clinical score over the 18-month study period. Some 
clinical improvement, in terms of reduction in clinical score, was seen in 96% 
of the patients in both the groups. Complete clearance of the lesions at 18 
months was seen in 45.6% and 37.5% of the patients receiving the WHO/ 
PB/MDT and the single dose ROM regimen respectively and the difference 
noted between the two groups in this regard was not statistically significant 
(P=0.30). 
Next, by sub-group analysis, we looked into the influence of some 
variables like age, number of lesions and the number of body parts affected 
on the treatment outcome. In terms of complete cure, ROM single dose 
regimen was almost as effective as WHO/PB/MDT in child patients and in 
patients with only two skin lesions. However, in adult patients and in patients 
with three skin lesions the standard WHO regimen for PB leprosy was found 
to be better than ROM regimen. When the disease was confined to a single 
part of the body, the single dose ROM regimen was as effective as the 
standard regimen, but when lesions were present on two different parts of 
the body, the standard regimen was significantly better than the single dose 
therapy. 
Another important factor to be monitored among these patients is the 
occurrence of reversal reaction and/or neurits. Ganapathy reported that during 
the first year of follow-up after ROM therapy the occurrence of reaction 
depended on the extent of the disease, viz. 1.7% in single lesion cases, 7.4% 
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in cases with 2-9 lesions and 14.7% in cases with more than ten lesions 
(Ganapathy et al 1998). We observed that only two adult patients under ROM 
therapy during the period of eighteen months developed reversal reaction. 
Also, none of the patients under ROM therapy developed any severe adverse 
drug reaction. 
As mentioned earlier, the relapse rate in PB leprosy is very low. About 
50% of the relapses among PB leprosy are expected to occur during first two 
years of surveillance. Moreover on clinical grounds it may be difficult in PB 
leprosy, to distinguish relapse from reversal reaction (WHO 1988). The 
present study is based on 236 patients and the follow-up period was only 18 
months. With this sample size, it is not possible to look for relapse, and 
surveillance beyond 11/2 years was not carried out. 
We found that single dose ROM therapy was safe and acceptable. We 
have attempted some sub-group analysis but it is based on small numbers. 
While instituting single dose ROM regimen care needs to be taken for 
selection of cases taking into account the age of the patient and the number 
of body parts affected. To understand the therapautic effect of single dose 
ROM therapy, over the entire spectrum of PB leprosy, possible relapse rates 
and its operational feasibility further field-based clinical trial under programme 
conditions is presently in progress. 
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